Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Hyde Park. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Hyde Park location
Preparing your pre-screening questions…
Access prostate cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
Check if you qualify for this prostate cancer clinical trial in Hyde Park, IL
No-Cost Study Care
Local to Hyde Park
Convenient for IL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance (AS) and radical therapy by destroying prostate cancer in a minimally invasive or non-invasive fashion and thus limiting the morbidity. This treatment strategy is increasingly being offered to patients due to low morbidity but the data on long term oncologic efficacy and side effect profile is lacking for such a treatment strategy. The purpose of this study is to create a database and prospective registry for data collection on patients with prostate cancer undergoing prostate ablation for the management of prostate cancer. Patients with biopsy-proven prostate cancer of any Gleason Grade will be entered into the registry as long as prostate ablation is used as the prostate cancer management modality. Historical data from 2017 to the present time will be added through chart review. Current and future patient data will be collected through chart review during the subject's clinical care. Only data available in the electronic medical record will be collected and no additional data will be collected for research purposes. No biospecimens will be collected, and there are no physical risks from study participation.
Sponsor: University of Chicago
Yes, this clinical trial (NCT06705803) has an active research site in Hyde Park, IL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for prostate cancer treatment options in Hyde Park, IL, this clinical trial (NCT06705803) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Hyde Park research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all prostate cancer clinical trials near you to find additional studies recruiting in your area.
See all prostate cancer clinical trials recruiting in Hyde Park — not just this study.
Browse Prostate Cancer Trials in Hyde Park →